Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.56 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.55 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | BMP1 | P13497 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15705617 | 0.92 | MAPT (0.65) | MEN1KMT2APTPN1ALDH1A1MAPT | |
| SCHEMBL15705623 | 0.92 | DAGLA (0.58) | MEN1KMT2APTPN1MAPTTAS2R14 | |
| SCHEMBL5295487 | 0.83 | TAS2R14 (0.64) | MEN1KMT2AALDH1A1MAPTTAS2R14 | |
| SCHEMBL2845552 | 0.81 | MEP1B (0.68) | MEN1KMT2AALDH1A1MAPTTAS2R14 | |
| SCHEMBL5093686 | 0.79 | ALDH1A1 (0.72) | ALDH1A1TAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL5092519 | 0.79 | KEAP1 (0.81) | ALDH1A1TAS2R14PTGESTAS2R8CXCR3 | |
| SCHEMBL5899440 | 0.79 | TAS2R14 (0.63) | MEN1KMT2AALDH1A1MAPTTAS2R14 | |
| SCHEMBL984791 | 0.79 | TAS2R14 (0.71) | MEN1KMT2APTPN1ALDH1A1MAPT | |
| SCHEMBL2513385 | 0.79 | TAS2R14 (0.70) | PTPN1ALDH1A1TAS2R14PTGESTAS2R8 | |
| SCHEMBL7338644 | 0.78 | MEP1B (0.81) | ALDH1A1TAS2R14PTGESTAS2R8CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139850-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2018-09-12 | — | — | EP | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | MEN1 1925/4885KMT2A 58/4885PTPN1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.